Science and technology company Merck has opened its new Sydney office in the innovation hub of Macquarie Park — a move that seeks to further the company's local growth opportunities.
The Melbourne drug development company has announced Dr Tim Oldham as its new CEO and signed a commercial agreement for its i-body platform with GE Healthcare.
Thermo Fisher Scientific has entered into a collaboration with Cedars-Sinai and elected Debora Spar to its board of directors.
Integrated DNA Technologies has announced two new partnerships as part of its mission to break down the barriers in genomics research.
The partnership fuses IDT's oligo synthesis with 3CR's PACE Genotyping Master Mix and expertise in designing assays.
With the support of the Victorian Government, Trajan Scientific and Medical plans to invest $2.4 million in the expansion of its Melbourne facility over the next three years.
Dow has successfully completed its separation from DowDuPont, becoming a more focused and streamlined materials science company in the process.
NanoString Technologies has announced a commercial agreement with Abcam for the manufacture and sale of antibodies specifically for use with NanoString's GeoMx Digital Spatial Profiler (DSP).
Serving science company Thermo Fisher Scientific has begun a collaborative project with Genovis, a provider of enzyme products for biological drug development, to develop end-to-end workflows for the preparation, characterisation and monitoring of novel and complex biotherapeutics using liquid chromatography-mass spectrometry (LC-MS).
Sartorius Stedim Biotech and Novasep have entered into a collaboration agreement in the area of chromatography and single-use bioprocessing.
A new international research laboratory, which aims to turbocharge scientific collaboration between Australia and France, is set to be established in Adelaide.
Thermo Fisher Scientific has signed a multiyear agreement with German immunotherapy company BioNTech, focused on supplying critical raw materials for the manufacturing of precise immunotherapy vaccine candidates.
The Australian Synchrotron is being used to conduct high-resolution 3D X-ray imaging of the femur of Australia's best known carnivorous dinosaur, Australovenator.
The collaborators aim to deliver platform workflows for simplified characterisation and quality monitoring of complex therapeutic proteins.
The foundation has three new areas of focus: entrepreneurship in science, leadership in our schools and guiding Australia's response to complex global legal issues.